tirzepatide heart side effects and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism Cardiovascular effects of tirzepatide -

Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha

Reusing needles increases the risk of infection and makes the injection more painful

Obesity and insulin resistance link to lower sperm count and altered semen parameters through inflammation and lowered testosterone

With it Im in the low 80s, high 70s

STEP 5 Trial A 104-week trial (the longest duration trial of the STEP program) which investigated the long-term effect of semaglutide 2.4 mg compared with placebo on body weight and cardiometabolic risk factors in adults with overweight or obesity

While they come from post-hoc analyses of an existing trial, the results build a picture of efficacy for oral semaglutide as Novo Nordisk prepares to compete in what is expected to be the next big frontier in obesity therapy the shift from injectable to daily oral therapies